R2 Dermatology was founded in late 2014 upon the licensing of technology created by scientists R. Rox Anderson, M.D., Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School; Dieter Manstein, M.D., Ph.D., of the Cutaneous Biology Research Center in the Department of Dermatology at Massachusetts General Hospital; and Henry H.L. Chan, M.D., Ph.D., Honorary Clinical Professor, Department of Medicine, The University of Hong Kong and the Visiting Scientist of the Wellman Center for Photomedicine, Massachusetts General Hospital.

Our lead investor is Pansend Life Sciences, LLC  — a wholly owned indirect subsidiary of HC2 Holdings (NYSE: HCHC). HC2 Holdings is a diversified holding company, which seeks to acquire and grow attractive businesses that generate sustainable free cash flow.

Our Board and Management Team are experienced in the areas of company formation, in transforming patented ideas into breakthrough procedures and products, and in the creation of compelling premium global brands.

Located in San Ramon, California, R2 has initiated early human clinical research and product development.